-68%

est. 2Y upside i

HealthcareSeries A

Rank

#1351

Sector

Biotechnology, AI Drug Discovery

Est. Liquidity

~4Y

Data Quality

Data: Medium

Peptone operates in the high-growth AI drug discovery market, specializing in intrinsically disordered proteins, a differentiated niche.

Last updated: March 10, 2026

Bull (18%)+400%

Successful clinical progress with an IDP-targeted therapeutic, potentially in oncology, leads to a major pharmaceutical partnership or acquisition at a significant premium, pushing valuation to $440M (5x current) within 2-4 years, capitalizing on the growing AI drug discovery market.

Base (50%)+50%

Continued platform development and strategic collaborations, such as the partnership with Evotec, achieving early clinical milestones and attracting further private funding rounds, resulting in a modest valuation increase to $132M (1.5x current) within 2-4 years.

Bear (32%)-80%

Clinical setbacks, increased competition from incumbents, or failure to secure next-round funding leads to a down round or distressed sale, reducing valuation to $17.6M (0.2x current) and significantly impacting common stock value due to severe liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

48%

Investors hold $42M in liquidation preferences ahead of common stock, representing 47.7% of the current $88M valuation. In an exit at or below current valuation, common stock holders may receive little to nothing.

Dilution Risk

high

As a Series A company with high capital intensity, Peptone will likely require several more funding rounds to bring drugs to market, leading to further dilution for early employees.

Secondary Liquidity

limited

A private secondary transaction occurred in July 2023, indicating some potential for liquidity, but there is no active public secondary market.

View all 2 open roles at Peptone →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Peptone's data — designed to show you've done your homework.

  • 1

    “Given the recent IPOs of AI drug discovery companies like Generate Biomedicines and Insilico Medicine, how does Peptone differentiate its approach to intrinsically disordered proteins to achieve a similar or even greater market impact and potential liquidity event?”

  • 2

    “With the reported 18% decrease in employee count last year, how is Peptone ensuring it retains critical talent and maintains its development velocity, especially given the high capital intensity of drug discovery?”

  • 3

    “Considering the Series A funding in 2022 and the long development cycles in biotech, what is the realistic timeline and strategy for a liquidity event (e.g., IPO or acquisition) that would provide meaningful returns for common stock holders, especially given the current preference stack?”

Community

Valuation Sentiment

Our model estimates -68% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.